Certara (CERT) announced the appointment of Christopher Bouton as CTO. In this role, Bouton will lead technology strategy and development of a next-generation integrated model-informed drug development platform, which is enabled by generative AI and advances in biosimulation technology. Bouton was the founder and CEO of Vyasa Analytics, acquired by Certara in 2022.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CERT: